Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
Lisa Derosa, Matthew D. Hellmann, Marco Spaziano, et al.
Annals of Oncology (2018) Vol. 29, Iss. 6, pp. 1437-1444
Open Access | Times Cited: 727

Showing 1-25 of 727 citing articles:

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi, Robert Yuan, Edgar G. Engleman
Annual Review of Pathology Mechanisms of Disease (2020) Vol. 16, Iss. 1, pp. 223-249
Open Access | Times Cited: 1564
Comprehensive review of targeted therapy for colorectal cancer
Yuanhong Xie, Yingxuan Chen, Jing‐Yuan Fang
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1305
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Golnaz Morad, Beth A. Helmink, Padmanee Sharma, et al.
Cell (2021) Vol. 184, Iss. 21, pp. 5309-5337
Open Access | Times Cited: 1065
The microbiome, cancer, and cancer therapy
Beth A. Helmink, Md Abdul Wadud Khan, Amanda Hermann, et al.
Nature Medicine (2019) Vol. 25, Iss. 3, pp. 377-388
Closed Access | Times Cited: 958
The microbiome and human cancer
Gregory D. Sepich‐Poore, Laurence Zitvogel, Ravid Straussman, et al.
Science (2021) Vol. 371, Iss. 6536
Open Access | Times Cited: 872
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
Khashayar Esfahani, Liya Roudaia, Najwa Buhlaiga, et al.
Current Oncology (2020) Vol. 27, Iss. 12, pp. 87-97
Open Access | Times Cited: 794
Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer
Aikun Fu, Bingqing Yao, Tingting Dong, et al.
Cell (2022) Vol. 185, Iss. 8, pp. 1356-1372.e26
Open Access | Times Cited: 580
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
David J. Pinato, Sarah Howlett, Diego Ottaviani, et al.
JAMA Oncology (2019) Vol. 5, Iss. 12, pp. 1774-1774
Open Access | Times Cited: 489
Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer
Winnie Fong, Qing Li, Jun Yu
Oncogene (2020) Vol. 39, Iss. 26, pp. 4925-4943
Open Access | Times Cited: 466
The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC
Yueping Jin, Hui Dong, Liliang Xia, et al.
Journal of Thoracic Oncology (2019) Vol. 14, Iss. 8, pp. 1378-1389
Open Access | Times Cited: 420
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas, et al.
Nature Medicine (2022) Vol. 28, Iss. 2, pp. 315-324
Open Access | Times Cited: 396
Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma
Michael B. Atkins, Nizar M. Tannir
Cancer Treatment Reviews (2018) Vol. 70, pp. 127-137
Open Access | Times Cited: 336
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Nazlı Dizman, Luís Meza, Paulo Gustavo Bergerot, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 704-712
Open Access | Times Cited: 314
Modulating the microbiome to improve therapeutic response in cancer
Jennifer L. McQuade, Carrie R. Daniel, Beth A. Helmink, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 2, pp. e77-e91
Open Access | Times Cited: 313
Turning cold tumors hot: from molecular mechanisms to clinical applications
Jiahui Zhang, Di Huang, Phei Er Saw, et al.
Trends in Immunology (2022) Vol. 43, Iss. 7, pp. 523-545
Closed Access | Times Cited: 312
Advances in clinical immunotherapy for gastric cancer
Kexin Li, Ashley Zhang, Xiaoya Li, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1876, Iss. 2, pp. 188615-188615
Closed Access | Times Cited: 302
Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients
Lisa Derosa, Bertrand Routy, Marine Fidelle, et al.
European Urology (2020) Vol. 78, Iss. 2, pp. 195-206
Open Access | Times Cited: 273
Exploring the emerging role of the microbiome in cancer immunotherapy
Jessica Fessler, Vyara Matson, Thomas F. Gajewski
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 269
The role of gut microbiota in cancer treatment: friend or foe?
Wing Yin Cheng, Chun‐Ying Wu, Jun Yu
Gut (2020) Vol. 69, Iss. 10, pp. 1867-1876
Open Access | Times Cited: 263
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Matthew D. Vesely, Tianxiang Zhang, Lieping Chen
Annual Review of Immunology (2022) Vol. 40, Iss. 1, pp. 45-74
Closed Access | Times Cited: 256
Gut microbiome and its role in colorectal cancer
Martina Reberšek
BMC Cancer (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 248
Gut microbiome, big data and machine learning to promote precision medicine for cancer
Giovanni Cammarota, Gianluca Ianiro, Anna M. Ahern, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 10, pp. 635-648
Closed Access | Times Cited: 241
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
Myriam Chalabi, Andrés F. Cardona, Deepti R. Nagarkar, et al.
Annals of Oncology (2020) Vol. 31, Iss. 4, pp. 525-531
Open Access | Times Cited: 239
Gut Microbiota in Cancer Immune Response and Immunotherapy
Cheng‐Bei Zhou, Yilu Zhou, Jing‐Yuan Fang
Trends in cancer (2021) Vol. 7, Iss. 7, pp. 647-660
Closed Access | Times Cited: 213
Nanotechnology intervention of the microbiome for cancer therapy
Wantong Song, Aaron C. Anselmo, Leaf Huang
Nature Nanotechnology (2019) Vol. 14, Iss. 12, pp. 1093-1103
Open Access | Times Cited: 206
Page 1 - Next Page

Scroll to top